Quick Answer
Celldex Therapeutics, Inc. reported Research And Development Expense of $245.07 million for the year ending 2025.
- Celldex Therapeutics, Inc. showed an increase of +49.8% in Research And Development Expense from 2024 to 2025.
- This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Celldex Therapeutics, Inc.'s Research And Development Expense has grown by 836.5%.
- Historical annual values: Fiscal year 2025: $245.07 million | Fiscal year 2024: $163.55 million | Fiscal year 2023: $118.01 million | Fiscal year 2022: $82.26 million | Fiscal year 2021: $53.31 million | Fiscal year 2020: $42.53 million | Fiscal year 2019: $42.67 million | Fiscal year 2018: $66.45 million | Fiscal year 2017: $96.17 million | Fiscal year 2016: $102.73 million | Fiscal year 2015: $100.17 million | Fiscal year 2014: $104.38 million | Fiscal year 2013: $67.40 million | Fiscal year 2012: $47.40 million | Fiscal year 2011: $32.44 million | Fiscal year 2010: $27.65 million | Fiscal year 2009: $26.17 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: